ABUS (STOCKS)
Arbutus Biopharma Corporation Common Stock
$4.320000
+0.060000 (+1.41%)
Prev close: $4.260000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Lindsay Androski
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $855.34M
- Employees
- 44
- P/E (TTM)
- 5.18
- P/B (TTM)
- 3.22
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.05 | $-0.03 | -0.0194 | -63.40% |
|
Dec 2025 (Q4)
|
$-0.02 | $-0.04 | +0.0157 | +43.98% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.03 | -0.0084 | -26.58% |
|
Jun 2025 (Q2)
|
$0.01 | $-0.05 | +0.0585 | +120.62% |
Financial Statements
| Revenues | $191.45M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $35.00M |
| Nonoperating Income/Loss | $4.27M |
| Operating Expenses | $35.00M |
| Research and Development | $20.40M |
| Other Operating Expenses | $14.60M |
| Operating Income/Loss | $156.45M |
| Income/Loss From Continuing Operations After Tax | $160.72M |
| Income/Loss From Continuing Operations Before Tax | $183.23M |
| Net Income/Loss | $160.72M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $160.72M |
| Net Income/Loss Available To Common Stockholders, Basic | $160.72M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.84 |
| Diluted Earnings Per Share | $0.83 |
| Basic Average Shares | 577,350,504 |
| Diluted Average Shares | 579,644,381 |
| Assets | $277.16M |
| Current Assets | $277.01M |
| Noncurrent Assets | $153.00K |
| Fixed Assets | $22.00K |
| Other Non-current Assets | $131.00K |
| Liabilities | $16.99M |
| Current Liabilities | $5.11M |
| Noncurrent Liabilities | $11.88M |
| Long-term Debt | $0.00 |
| Equity | $260.18M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $260.18M |
| Liabilities And Equity | $277.16M |
| Net Cash Flow From Operating Activities | -$34.36M |
| Net Cash Flow From Operating Activities, Continuing | -$34.36M |
| Net Cash Flow From Investing Activities | $6.43M |
| Net Cash Flow From Investing Activities, Continuing | $6.43M |
| Net Cash Flow From Financing Activities | $14.56M |
| Net Cash Flow From Financing Activities, Continuing | $14.56M |
| Exchange Gains/Losses | $0.00 |
| Net Cash Flow | -$13.37M |
| Net Cash Flow, Continuing | -$13.37M |
| Comprehensive Income/Loss | $160.71M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $160.69M |
| Other Comprehensive Income/Loss | $158.19M |